SCHEMBL419057

SCHEMBL419057

COC(=O)c1cc(Cl)ccc1NC(=O)c1cccc(-c2ccoc2)c1

nearest known ligand 0.78

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 11/20 0.78
PLAU P00749 1/20 0.49
SUCNR1 Q9BXA5 1/20 0.49
AKR1C4 P17516 1/20 0.49
AKR1C3 P42330 1/20 0.49
AKR1C2 P52895 1/20 0.49
AKR1C1 Q04828 1/20 0.49
MAPT P10636 1/20 0.47
CNR1 P21554 1/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HDAC2 Q92769 1/20 0.47
LCLAT1 Q6UWP7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL420979 0.88 SERPINE1 (1.00) SERPINE1SUCNR1AKR1C4AKR1C3AKR1C2
SCHEMBL420185 0.87 SERPINE1 (0.77) SERPINE1PLAUSUCNR1AKR1C4AKR1C3
SCHEMBL417030 0.86 SERPINE1 (0.59) SERPINE1PLAUCNR1NPC1
SCHEMBL1015090 0.84 SERPINE1 (0.79) SERPINE1MAPTCNR1NPC1ALDH1A1
SCHEMBL421465 0.84 SERPINE1 (0.65) SERPINE1PLAUSUCNR1AKR1C4AKR1C3
SCHEMBL417914 0.83 SERPINE1 (0.64) SERPINE1PLAUSUCNR1AKR1C4AKR1C3
SCHEMBL418556 0.82 SERPINE1 (0.61) SERPINE1CNR1NPC1ALDH1A1HPGD
SCHEMBL416816 0.82 SERPINE1 (0.53) SERPINE1CNR1NPC1ALDH1A1HPGD
SCHEMBL419000 0.81 SERPINE1 (0.60) SERPINE1CNR1NPC1ALDH1A1HPGD
SCHEMBL419148 0.81 SERPINE1 (0.82) SERPINE1MAPTNPC1ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PLAU 11/4885SUCNR1 4454/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885PLAU 11/4885SUCNR1 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.